Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript May 1, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations.
Phathom Pharmaceuticals Inc. (PHAT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Decheng Capital Min Cui | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.40 | 5,000 | 95,500 | 2025-05-07 | Filing | ||
| $2.60 | 5,000 | 90,500 | 2025-05-06 | Filing | ||
| $4.42 | 10,000 | 85,500 | 2025-03-13 | Filing | ||
| $7.93 | 12,500 | 57,000 | 2024-12-13 | Filing | ||
| $8.12 | 10,000 | 75,500 | 2024-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.55 | 3,678 | 89,868 | 2025-04-07 | Filing | ||
| $6.59 | 6,583 | 93,546 | 2025-01-21 | Filing | ||
| $6.59 | 7,886 | 233,390 | 2025-01-21 | Filing | ||
| $6.59 | 19,109 | 360,465 | 2025-01-21 | Filing | ||
| $8.00 | 1,118 | 239,303 | 2024-12-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,464,572 | $46,802,866 | 10.69% | |
| 2. | 7,042,325 | $44,155,377 | 0.03% | |
| 3. | 3,496,808 | $21,924,986 | 0.58% | |
| 4. | 3,323,603 | $20,838,990 | 0% | |
| 5. | 2,778,687 | $17,422,368 | 0% |
News See All
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?
PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. At this time, all participants are in a listen-only mode.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2024 Earnings Call Transcript
Operator: Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
12 Most Shorted Stocks in 2024
Short-sellers may be annoying for corporations (and Redditors?), but investors usually find themselves thanking these companies for doing the often back-breaking and excruciating research that is required...
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.8, expectations were $-0.92.
Hedge Fund and Insider Trading News: Amber Capital UK LLP, Third Point LLC, D.E. Shaw, Odey Asset Management, Alameda Research, North Rock Digital, FedEx Corp (FDX), Domo, Inc. (DOMO), and More
Amber Capital UK LLP founder Joseph Oughourlian denied a news report that claimed he was in talks with several private equity funds to take control of Spanish defense group Indra Sistemas SA.
Hedge Fund and Insider Trading News: Anthony Scaramucci, Nelson Peltz, Bill Ackman, Leon Cooperman, Standard General LP, Comtech Telecomm. Corp. (CMTL), Tilly's, Inc. (TLYS), and More
SkyBridge Capital can buy back the stake it sold to collapsed cryptocurrency exchange FTX but the issue will likely take months to resolve, the investment firm’s founder Anthony Scaramucci told CNBC...